Clinical Development Setbacks, Pricing Pressures Hit Top, Bottom Lines at Roche
This article was originally published in The Pink Sheet Daily
"The financial crisis has arrived for the pharmaceutical industry," says CEO Severin Schwan.
You may also be interested in...
Adding bevacizumab to chemo in first-line and maintenance therapy gives an undisclosed benefit in progression-free survival.
Roche’s Soriot will take over as CEO of Genentech, while key members of Genentech’s management will take on advisory roles or depart.
With Roche's unsolicited attempt to buy out Genentech's minority shareholders for $89 dollars a share, a bid totaling nearly $44 billion, the company is wagering heavily that it will not destroy one of the industry's most successful pharma-biotech collaborations. But has Roche laid out a straight flush or lost its ace to a bluff